H Zippel1, A Wagenitz. 1. Department of Orthopaedics, Charité-University Medicine, Berlin, Germany.
Abstract
BACKGROUND: Low back pain is an important medical problem in Western industrialised countries. NSAIDs are one of the main options for symptomatic pain relief in the early management of this painful condition. Dexketoprofen is an NSAID belonging to the arylpropionic acid group that has demonstrated good analgesic efficacy and a good safety profile in different acute and chronic painful conditions. METHODS: A randomised, double-blind, parallel, active controlled, multicentre study that included 370 outpatients with acute low back pain was conducted to compare the analgesic efficacy of dexketoprofen 50mg twice daily versus diclofenac 75mg twice daily administered intramuscularly for 2 days. Efficacy outcomes were assessment of pain intensity (PI) measured on a visual analogue scale, total PI scores from baseline to 6 hours after the first-dose administration (primary efficacy endpoint; SAPID(0-6)), score on a physical disability scale using the Roland Disability Questionnaire (RDQ), and use of rescue medication. Tolerability and safety were also assessed as secondary variables. RESULTS: The adjusted mean (SAPID(0-6)) scores were very similar, 117.3 mm/h with dexketoprofen and 114.7 mm/h with diclofenac. The adjusted ratio of means was 1.023 and the lower 95% confidence limit was 0.81, demonstrating non-inferiority of dexketoprofen (defined by a lower limit of the 95% CI >0.80) in comparison with diclofenac (per-protocol analysis). The median change in the RDQ was -6 points for both groups (p = 0.69), showing an overall improvement on the disability scale. No significant differences between groups were observed regarding the percentage of patients needing rescue medication or in the mean values of pain after repeated doses (SAPID(0-last)). Dexketoprofen was well tolerated, with a reported incidence of adverse events similar to that of diclofenac. No serious adverse events were reported in either treatment group. CONCLUSION: From the results of this study it can be concluded that dexketoprofen 50mg administered twice daily intramuscularly provides a clinically relevant analgesic effect with good tolerability after single and repeated doses in patients with acute severe low back pain.
RCT Entities:
BACKGROUND:Low back pain is an important medical problem in Western industrialised countries. NSAIDs are one of the main options for symptomatic pain relief in the early management of this painful condition. Dexketoprofen is an NSAID belonging to the arylpropionic acid group that has demonstrated good analgesic efficacy and a good safety profile in different acute and chronic painful conditions. METHODS: A randomised, double-blind, parallel, active controlled, multicentre study that included 370 outpatients with acute low back pain was conducted to compare the analgesic efficacy of dexketoprofen 50mg twice daily versus diclofenac 75mg twice daily administered intramuscularly for 2 days. Efficacy outcomes were assessment of pain intensity (PI) measured on a visual analogue scale, total PI scores from baseline to 6 hours after the first-dose administration (primary efficacy endpoint; SAPID(0-6)), score on a physical disability scale using the Roland Disability Questionnaire (RDQ), and use of rescue medication. Tolerability and safety were also assessed as secondary variables. RESULTS: The adjusted mean (SAPID(0-6)) scores were very similar, 117.3 mm/h with dexketoprofen and 114.7 mm/h with diclofenac. The adjusted ratio of means was 1.023 and the lower 95% confidence limit was 0.81, demonstrating non-inferiority of dexketoprofen (defined by a lower limit of the 95% CI >0.80) in comparison with diclofenac (per-protocol analysis). The median change in the RDQ was -6 points for both groups (p = 0.69), showing an overall improvement on the disability scale. No significant differences between groups were observed regarding the percentage of patients needing rescue medication or in the mean values of pain after repeated doses (SAPID(0-last)). Dexketoprofen was well tolerated, with a reported incidence of adverse events similar to that of diclofenac. No serious adverse events were reported in either treatment group. CONCLUSION: From the results of this study it can be concluded that dexketoprofen 50mg administered twice daily intramuscularly provides a clinically relevant analgesic effect with good tolerability after single and repeated doses in patients with acute severe low back pain.
Authors: Maurits van Tulder; Annette Becker; Trudy Bekkering; Alan Breen; Maria Teresa Gil del Real; Allen Hutchinson; Bart Koes; Even Laerum; Antti Malmivaara Journal: Eur Spine J Date: 2006-03 Impact factor: 3.134
Authors: M McGurk; P Robinson; V Rajayogeswaran; M De Luca; A Casini; R Artigas; G Muñoz; D Mauleón Journal: J Clin Pharmacol Date: 1998-12 Impact factor: 3.126
Authors: J Beltrán; E Martín-Mola; M Figueroa; J Granados; R Sanmartí; R Artigas; F Torres; M Forns; D Mauleón Journal: J Clin Pharmacol Date: 1998-12 Impact factor: 3.126
Authors: Sanjog S Pangarkar; Daniel G Kang; Friedhelm Sandbrink; Adam Bevevino; Kirsten Tillisch; Lisa Konitzer; James Sall Journal: J Gen Intern Med Date: 2019-09-16 Impact factor: 5.128
Authors: P T Jamdade; A Porwal; J V Shinde; S S Erram; V V Kamat; P S Karmarkar; K Bhagtani; S Dhorepatil; R Irpatgire; H Bhagat; S S Kolte; P A Shirure Journal: Anesthesiol Res Pract Date: 2011-05-12
Authors: Wendelien H van der Gaag; Pepijn Ddm Roelofs; Wendy Tm Enthoven; Maurits W van Tulder; Bart W Koes Journal: Cochrane Database Syst Rev Date: 2020-04-16